Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Alx Oncology Holdings (ALXO) Debt to Equity (2019 - 2023)

Alx Oncology Holdings' Debt to Equity history spans 5 years, with the latest figure at $0.06 for Q3 2023.

  • For Q3 2023, Debt to Equity rose 209.61% year-over-year to $0.06; the TTM value through Sep 2023 reached $0.06, up 209.61%, while the annual FY2022 figure was $0.04, 402.03% up from the prior year.
  • Debt to Equity for Q3 2023 was $0.06 at Alx Oncology Holdings, up from $0.04 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.06 in Q3 2023 and bottomed at -$0.08 in Q4 2019.
  • The 5-year median for Debt to Equity is $0.02 (2020), against an average of $0.01.
  • The largest annual shift saw Debt to Equity soared 402.03% in 2022 before it skyrocketed 181.52% in 2023.
  • A 5-year view of Debt to Equity shows it stood at -$0.08 in 2019, then skyrocketed by 129.78% to $0.02 in 2020, then plummeted by 63.48% to $0.01 in 2021, then skyrocketed by 402.03% to $0.04 in 2022, then surged by 35.42% to $0.06 in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Debt to Equity are $0.06 (Q3 2023), $0.04 (Q2 2023), and $0.04 (Q1 2023).